• Skip to main content
  • Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu
  • HOME
  • ABOUT
    • Close
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PEDIATRIC HSCT-TMA
    • GEOGRAPHIC ATROPHY (GA)
  • THE SCIENCE
    • Close
    • OVERVIEW
    • MODE OF ACTION
    • TARGET PATHWAYS
      • Close
      • C5 (COMPLEMENT SYSTEM)
      • LTB4 (LEUKOTRINE SYSTEM)
    • MOLECULES
      • Close
      • NOMACOPAN
      • OTHER NOMACOPAN-BASED MOLECULES
      • VOTUCALIS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING OF SHAREHOLDERS
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & EVENTS
      • Close
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • INVESTOR RESOURCES
      • Close
      • INVESTOR FAQS
      • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • PUBLICATIONS
    • STORIES
  • CONTACT US

Stories

Akari TX / December 14, 2022

Check out the discussion transcript from The Science Huddle: Small Data Big Outcomes

CLICK TO READ ENTIRE TRANSCRIPT With the reach and impact of biopharma growing exponentially, experts in biotech and the evolving regulatory environment came …

[Read more...] about Check out the discussion transcript from The Science Huddle: Small Data Big Outcomes

Akari TX / November 22, 2022

Akari on the Business of Biotech podcast

Ticks aren’t all bad! Check out the Business of Biotech podcast to hear how Akari engineered #nomacopan, a recombinant protein derived from ticks, and scaled …

[Read more...] about Akari on the Business of Biotech podcast

Akari TX / October 6, 2022

Rich Database Underpins Predictive PK/PD Model

Akari clinical data from 38 subjects (in previous clinical studies and healthy volunteers) support robust PK/PD model simulations used to select doses for …

[Read more...] about Rich Database Underpins Predictive PK/PD Model

Akari TX / October 4, 2022

Simulated 10,000 Virtual Patients

Akari's robust PK/PD model simulated 10,000 virtual patients informing U.S. FDA MIDD interactions that helped confirm PK/PD model suitability & doses …

[Read more...] about Simulated 10,000 Virtual Patients

Akari TX / September 2, 2022

Thrombotic Microangiopathy

Thrombotic microangiopathy following a stem cell transplant is a rare but serious complication that often leads to progressive organ damage and death. Akari is …

[Read more...] about Thrombotic Microangiopathy

Next Page »

Footer

Akari TX

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

1460 Broadway
New York, NY 10036

T: 929.274.7510
F: 929.274.7553
E: info@Akaritx.com

For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com

REGISTERED ADDRESS

Akari Therapeutics, Plc is registered in England and Wales under number 5252842 and has its registered office at Highdown House, Yeoman Way, Worthing, West Sussex, BN99 3HH.

EXPANDED ACCESS POLICY

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access.  At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Copyright © 2023 · Akari Therapeutics · Site Designed by Polus Digital, Inc.